ReviewNanomedicine (London, England)2025
Beyond biologics: fungal polysaccharides as dual-function materials for nanomedicine.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Empowering cancer therapy: the promise of natural adjuvants.Molecular biology reports · 2026Review
- Fungal Polysaccharides as Modulators of Molecular Pathways in Liver Health.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal polysaccharides exhibit a unique dual role in nano-delivery systems as both bioactive agents and functional carrier materials. Their intrinsic biocompatibility, biodegradability, and immunomodulatory properties enable applications in cancer therapy, immunoregulation, inflammation control, and nutrient delivery. As active components, their therapeutic efficacy is often limited by poor solubility and low bioavailability - issues that can be overcome via nanotechnology strategies such as encapsulation in nanoparticles, nanogels, and nanoemulsions. When used as carriers, fungal polysaccharides offer high drug-loading capacity, tunable surface chemistry, and inherent immune-targeting potential. They enable controlled release, improved stability, and synergistic effects in combination therapies and vaccine adjuvants. However, challenges remain in structural standardization, reproducibility, and understanding structure - activity relationships - particularly regarding higher-order conformations and their biological implications. This review summarizes recent advances in fungal polysaccharide-based nano-delivery systems, emphasizing their structural attributes, formulation strategies, and multifunctional therapeutic roles. It also outlines future directions, including smart carrier design, stimuli-responsiveness, and scalable production. A deeper understanding of their structural biology will guide the rational development of safe and efficient polysaccharide-based nanoplatforms for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.